ReviewThe Journal of clinical investigation2011
Insight into the heterogeneity of breast cancer through next-generation sequencing.
Review in The Journal of clinical investigation, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 123 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
123 citing papers in PubMed.
- Response prediction of neoadjuvant chemoradiation therapy in locally advanced rectal cancer using CT-based fractal dimension analysis.European radiology · 2022Trial
- Trial
- Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/AKT/mTOR pathway.Oncotarget · 2014Trial
- Forcing the code: tension modulates signaling to drive morphogenesis and malignancy.Genes & development · 2025Review
- Texture analysis of CT colonography to develop a novel imaging biomarker for the management of colorectal cancer.Annals of gastroenterological surgery · 2025Article
- Multimodal diagnostic models and subtype analysis for neoadjuvant therapy in breast cancer.Frontiers in immunology · 2025Article
- Immunohistochemical Evaluation of Cathepsin B, L, and S Expression in Breast Cancer Patients.Molecular imaging and biology · 2024Article
- [Journal of clinical medicine · 2024Review
- Comprehensive genomic profiling and therapeutic implications for Taiwanese patients with treatment-naïve breast cancer.Cancer medicine · 2024Article
- Evolution of chromosome-arm aberrations in breast cancer through genetic network rewiring.Cell reports · 2024Article
- Article
- A Bayesian framework to study tumor subclone-specific expression by combining bulk DNA and single-cell RNA sequencing data.Genome research · 2024Article
- Unveiling the role of SYNGR4 in breast cancer development: a novel target for immunotherapy.Frontiers in oncology · 2024Article
- Omics Technologies Improving Breast Cancer Research and Diagnostics.International journal of molecular sciences · 2023Review
- Breast Cancer Statistics in Korea, 2019.Journal of breast cancer · 2023Review
- A Pilot Study on Biochemical Profile of Follicular Fluid in Breast Cancer Patients.Metabolites · 2023Article
- High levels of unfolded protein response component CHAC1 associates with cancer progression signatures in malignant breast cancer tissues.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Article
- Combination treatment with hENT1 and miR-143 reverses gemcitabine resistance in triple-negative breast cancer.Cancer cell international · 2022Article
- Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer.Genes · 2022Article
- Breast cancer heterogeneity through the lens of single-cell analysis and spatial pathologies.Seminars in cancer biology · 2022Review
63 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rapid and sophisticated improvements in molecular analysis have allowed us to sequence whole human genomes as well as cancer genomes, and the findings suggest that we may be approaching the ability to individualize the diagnosis and treatment of cancer. This paradigmatic shift in approach will require clinicians and researchers to overcome several challenges including the huge spectrum of tumor types within a given cancer, as well as the cell-to-cell variations observed within tumors. This review discusses how next-generation sequencing of breast cancer genomes already reveals insight into tumor heterogeneity and how it can contribute to future breast cancer classification and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.